Zydus Therapeutics Inc.
Clinical trials sponsored by Zydus Therapeutics Inc., explained in plain language.
-
New hope for PBC: drug aims to slow liver damage
Disease control Not yet recruitingThis study tests a drug called saroglitazar magnesium in people with primary biliary cholangitis (PBC), a chronic liver disease. About 386 adults who are already on standard treatment will receive either the drug or a placebo for a long period. The goal is to see if the drug can …
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:54 UTC
-
New hope for PBC patients: phase 3 trial of saroglitazar launches
Disease control Not yet recruitingThis study tests a new drug, saroglitazar magnesium, in 89 adults with primary biliary cholangitis (PBC) who did not get enough benefit from or could not tolerate standard treatment (UDCA). The goal is to see if the drug can lower a key liver enzyme (alkaline phosphatase) to norm…
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC